openPR Logo
Press release

Community-Acquired Bacterial Pneumonia (CABP) Market Growth, Applications, Innovations and Business Outlook by 2034

09-03-2025 11:43 AM CET | Health & Medicine

Press release from: Exactitude Consultancy

Community-Acquired Bacterial Pneumonia (CABP) Market

Community-Acquired Bacterial Pneumonia (CABP) Market

Introduction
Community-acquired bacterial pneumonia (CABP) remains one of the most significant infectious diseases globally, particularly among the elderly, immunocompromised patients, and individuals with chronic comorbidities. Caused primarily by Streptococcus pneumoniae, CABP accounts for millions of hospitalizations each year, posing a substantial healthcare and economic burden.

With the rise of antibiotic resistance, aging populations, and post-viral pneumonia cases, demand for effective treatments and preventive strategies is increasing. The CABP Market is undergoing transformation as pharmaceutical companies launch next-generation antibiotics, expand vaccination programs, and integrate rapid diagnostics to support targeted therapies.

Download Full PDF Sample Copy of Market Report @
https://exactitudeconsultancy.com/request-sample/71472

Market Overview
• Market Size 2024: Estimated at USD 10.5 billion
• Forecast 2034: Projected to reach USD 16.9 billion
• CAGR (2024-2034): ~4.9%

Key Highlights
• Rising CABP incidence due to aging populations and comorbid conditions (COPD, diabetes, heart disease).
• Growth in vaccination programs targeting Streptococcus pneumoniae.
• Launch of novel antibiotics and combination therapies to combat resistant strains.
• Increased adoption of point-of-care diagnostic tools for faster treatment decisions.

Segmentation Analysis
By Drug Class
• Macrolides (azithromycin, clarithromycin)
• Fluoroquinolones (levofloxacin, moxifloxacin)
• Beta-lactams (amoxicillin, cephalosporins)
• Tetracyclines (doxycycline)
• Combination Therapies
• Novel Antibiotics (ceftaroline, lefamulin, omadacycline)

By Route of Administration
• Oral
• Intravenous (IV)

By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By End User
• Hospitals
• Specialty Clinics
• Ambulatory Care Centers
• Homecare Settings

Summary:
While macrolides and beta-lactams remain widely prescribed, novel antibiotics like lefamulin and omadacycline are gaining traction for resistant CABP cases. Oral therapies dominate outpatient care, while IV formulations are critical for hospitalized patients.

Explore Full Report here:
https://exactitudeconsultancy.com/reports/71472/community-acquired-bacterial-pneumonia-market

Regional Analysis
North America
• Largest market share in 2024, driven by the U.S.
• High prevalence of pneumonia in elderly populations.
• Strong adoption of PCV13 and PCV20 pneumococcal vaccines.
• Rapid uptake of novel antibiotics and stewardship programs.
Europe
• Widespread vaccination campaigns across Germany, France, and the UK.
• Stringent antibiotic prescribing guidelines promoting targeted therapy.
• Increasing use of rapid diagnostics in hospitals.
Asia-Pacific
• Fastest-growing region (CAGR ~6.2%).
• High pneumonia burden in China, India, and Southeast Asia due to pollution and aging demographics.
• Expanding government immunization initiatives.
• Rising investment in local antibiotic production and distribution.
Latin America
• Brazil and Mexico dominate the regional market.
• Increasing government programs for pneumococcal vaccination.
• Limited antibiotic availability in rural and low-resource settings.
Middle East & Africa
• Growing incidence due to high rates of smoking and respiratory diseases.
• GCC nations improving hospital infrastructure and vaccine coverage.
• Access challenges persist in Sub-Saharan Africa.

Summary:
While North America and Europe currently lead, Asia-Pacific will be the fastest-growing region due to its high patient pool, government vaccination programs, and expanding healthcare systems.

Market Dynamics
Key Growth Drivers
• Rising global incidence of pneumonia, especially in elderly populations.
• Advancements in next-generation antibiotics.
• Expansion of pneumococcal vaccination programs.
• Increasing adoption of rapid diagnostics and telemedicine.

Key Challenges
• Growing threat of antibiotic resistance.
• High treatment costs for novel antibiotics.
• Limited access to vaccines and therapies in low-income regions.

Latest Trends
• Development of broad-spectrum and resistance-targeted antibiotics.
• Growing pipeline of pleuromutilins (e.g., lefamulin) for CABP.
• Integration of AI-driven diagnostic platforms for rapid pneumonia detection.
• Rising importance of hospital antibiotic stewardship programs.

Get Your Exclusive Offer with up to 10% Discount :
https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=71472

Competitor Analysis
Major Players
• Pfizer Inc. - Prevnar (PCV13/PCV20) vaccines, antibiotics portfolio.
• Merck & Co., Inc. - Pneumovax 23 vaccine, antibacterial therapies.
• AstraZeneca plc - Research in respiratory infection therapies.
• GlaxoSmithKline plc (GSK) - Vaccines and antibiotics.
• Sanofi - Pneumococcal vaccination initiatives.
• Novartis AG - Antibiotic and respiratory drug pipeline.
• Bayer AG - Fluoroquinolone antibiotics.
• Nabriva Therapeutics - Lefamulin for CABP.
• Paratek Pharmaceuticals - Omadacycline.
• Melinta Therapeutics - Advanced anti-infective therapies.

Competitive Summary:
The CABP market is moderately consolidated, with Pfizer, Merck, and GSK dominating vaccines and antibiotics. Meanwhile, smaller firms such as Nabriva and Paratek are driving innovation in next-generation CABP therapies. Strategic partnerships and government vaccine contracts play a key role in competitive positioning.

Conclusion
The Community-Acquired Bacterial Pneumonia Market is projected to expand from USD 10.5 billion in 2024 to USD 16.9 billion by 2034, growing at a steady CAGR of 4.9%. The market is being shaped by aging populations, vaccination programs, and the rise of novel antibiotics.
While antibiotic resistance and access barriers remain major challenges, the adoption of innovative therapies, rapid diagnostics, and AI-driven tools is expected to improve treatment outcomes and reduce hospital burden.

Key Takeaway: Companies investing in next-generation antibiotics, vaccine development, and precision diagnostic solutions will be best positioned to capture long-term growth in the CABP market.

This report is also available in the following languages : Japanese (市中感染性細菌性肺炎市場), Korean (지역사회 감염성 세균성 폐렴 시장), Chinese (社区获得性细菌性肺炎市场), French (Marché de la pneumonie bactérienne acquise dans la communauté), German (Markt für ambulant erworbene bakterielle Lungenentzündung), and Italian (Mercato della polmonite batterica acquisita in comunità), etc.

Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @
https://exactitudeconsultancy.com/request-sample/71472

Our More Reports:

Hepatic Impairment Market
https://exactitudeconsultancy.com/reports/71536/hepatic-impairment-market

Cutaneous Lupus Erythematosus (CLE) Market
https://exactitudeconsultancy.com/reports/71538/cutaneous-lupus-erythematosus-cle-market

Soft Tissue Defect Market
https://exactitudeconsultancy.com/reports/71544/soft-tissue-defect-market

About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.

https://bulletin.exactitudeconsultancy.com/

https://www.thehealthanalytics.com/

https://www.analytica.global/

https://www.marketintelligencedata.com/

https://www.marketinsightsreports.com/

https://exactitudeconsultancy.com/

Connect Us:
IRFAN TAMBOLI
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Community-Acquired Bacterial Pneumonia (CABP) Market Growth, Applications, Innovations and Business Outlook by 2034 here

News-ID: 4168039 • Views:

More Releases from Exactitude Consultancy

Concussion Market to Reach USD 11.9 Billion by 2034, Growing at 4.8% CAGR
Concussion Market to Reach USD 11.9 Billion by 2034, Growing at 4.8% CAGR
Introduction Concussions, a form of mild traumatic brain injury (mTBI), are increasingly recognized as a major public health issue. Once overlooked or misdiagnosed, they are now understood to have long-term neurological consequences if untreated. Growing awareness, combined with advances in imaging, biomarkers, digital health tools, and rehabilitation, has positioned the concussion market for sustained growth. The surge in sports-related injuries, road accidents, workplace trauma, and military-related head injuries has created significant demand
Testicular Neoplasm Market to Reach USD 2.9 Billion by 2034 | Bristol Myers Squibb, Novartis AG
Testicular Neoplasm Market to Reach USD 2.9 Billion by 2034 | Bristol Myers Squi …
Testicular neoplasms, also referred to as testicular cancers, represent the most common malignancy in males aged 15-40 years. Although relatively rare compared to other cancers, they are highly treatable, with survival rates exceeding 95% when detected early. Testicular neoplasms include germ cell tumors (seminomas and non-seminomas) and less common stromal tumors. Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/72863 Growing awareness, improved screening, and the availability of advanced treatment options
A Case Report of Charcot-Marie-Tooth Disease Associated with Severe Hand Contractures and Respiratory Failure Needing Continuous Ventilator Support
A Case Report of Charcot-Marie-Tooth Disease Associated with Severe Hand Contrac …
Charcot-Marie-Tooth disease (CMT) is one of the most common inherited neurological disorders, affecting the peripheral nerves responsible for muscle movement and sensory information. It typically leads to progressive muscle weakness, foot deformities, balance problems, and sensory loss. Although CMT is not life-threatening, it significantly impacts quality of life due to disability and progressive functional decline. Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/72865 CMT encompasses multiple subtypes, such as CMT1,
The connection between Chinese children's Meibomian Gland Dysfunction and dry eye illness and childhood obesity
The connection between Chinese children's Meibomian Gland Dysfunction and dry ey …
Meibomian gland dysfunction (MGD) is one of the most common causes of dry eye disease (DED), a condition affecting millions globally. MGD occurs when the meibomian glands, located in the eyelids, fail to secrete enough oil or produce poor-quality oil, leading to rapid tear evaporation. The result is ocular discomfort, irritation, redness, and blurred vision. Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/72867 Rising screen time, environmental stressors, and aging

All 5 Releases


More Releases for CABP

Community-Acquired Bacterial Pneumonia (CABP) Market is expected to reach USD 14 …
Community-acquired bacterial pneumonia (CABP) is a serious lung infection contracted outside hospital or healthcare settings, most commonly caused by Streptococcus pneumoniae, Haemophilus influenzae, Mycoplasma pneumoniae, and other bacterial pathogens. It remains a leading cause of morbidity, mortality, and healthcare costs worldwide, particularly among children, elderly populations, and immunocompromised patients. Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71735 The CABP market is driven by rising incidence, antimicrobial resistance (AMR), approvals of
Community-Acquired Bacterial Pneumonia (CABP) Pipeline Analysis 2025: EMA, PDMA, …
(Albany, United States) "Community-Acquired Bacterial Pneumonia (CABP) Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Community-Acquired Bacterial Pneumonia (CABP) Market. As per DelveInsight's assessment, globally, Community-Acquired Bacterial Pneumonia (CABP) pipeline constitutes of key companies continuously working towards developing Community-Acquired Bacterial Pneumonia (CABP) treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. The
From Bench to Bedside: Optimizing Treatment Pathways for Community-acquired Bact …
The "Community-acquired Bacterial Pneumonia  (CABP) Treatment Market was valued for $6.5 billion in 2024 and is estimated to reach $18.5 billion by 2031, exhibiting a CAGR of 11.2% from 2024 to 2031. Coherent Market Insights has released a statistical report titled "Community-acquired Bacterial Pneumonia  (CABP) Treatment Market Recent Trends, In-depth Analysis, Size, and Forecast 2024-2031." This report offers a comprehensive overview of the competitive landscape, geographical segmentation, innovation, future
Community-Acquired Bacterial Pneumonia (CABP) Market to Register Incremental Gro …
DelveInsight's "Community-Acquired Bacterial Pneumonia Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Community-Acquired Bacterial Pneumonia, historical and forecasted epidemiology as well as the Community-Acquired Bacterial Pneumonia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. To Know in detail about the Community-Acquired Bacterial Pneumonia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Community-Acquired Bacterial Pneumonia
Community-acquired Bacterial Pneumonia (CABP) Treatment Drugs Market to Overall …
The global Community-acquired Bacterial Pneumonia (CABP) Treatment Drugs market size was valued at $ 1,269.73 Mn in 2020, and is projected to reach $ 2,075.34 Mn by 2027, registering a CAGR of 7.5% from 2020 to 2027. Coherent Market Insights added new research on Community-acquired Bacterial Pneumonia (CABP) Treatment Drugs Market- Opportunity Analysis and Industry Forecast, 2022-2028. The Community-acquired Bacterial Pneumonia (CABP) Treatment Drugs market explores comprehensive study on various
Community-acquired Bacterial Pneumonia (CABP) Treatment Drugs Market Growth in F …
Coherent Market Insights has released a new research study on the "Community-acquired Bacterial Pneumonia (CABP) Treatment Drugs Market" which aims to provide a thorough examination of the factors influencing global business introduction and outlook. The Global Community-acquired Bacterial Pneumonia (CABP) Treatment Drugs Market Report detailed information and overview highlight the most recent trends in various regions. Leading market participants will benefit from the trading insights provided in this report. The